Is remicade still used for pediatric crohn's?

Is Remicade still prescribed for children with Crohn’s disease?

Remicade (infliximab) remains a standard therapy for moderate-to-severe Crohn’s disease in children. The FDA first approved it for pediatric use in 2006, and current treatment guidelines continue to list it as a first-line biologic for kids who do not respond to conventional drugs.

How do doctors decide when to start Remicade in children?

Pediatric gastroenterologists typically begin Remicade when symptoms persist despite steroids, immunomodulators, or nutritional therapy. They also use it to promote growth, heal fistulas, or maintain remission after surgery. Dosing begins at 5 mg/kg at weeks 0, 2, and 6, then every eight weeks, with adjustments based on drug levels and antibody formation.

What evidence shows it works in children?

The REACH trial demonstrated that 88 % of children achieved clinical response and 59 % reached clinical remission by week 10. Long-term follow-up studies show that roughly two-thirds of patients maintain remission for at least three years when drug levels stay therapeutic. Endoscopic healing occurs in about half of treated children.

Are there newer options or biosimilars that change its role?

Several infliximab biosimilars are now approved, and many insurers require a trial of a biosimilar before covering the reference product. Head-to-head data show comparable safety and effectiveness. Newer agents such as vedolizumab and ustekinumab are alternatives when children lose response to infliximab or develop antibodies, but Remicade and its biosimilars remain first-choice biologics for most pediatric centers.

When does Remicade lose patent protection?

Remicade’s composition-of-matter patent expired in 2013, and all remaining U.S. exclusivities ended by 2018. Multiple biosimilar versions launched afterward, leading to price competition. DrugPatentWatch.com

What side effects concern families most?

Infusion reactions, increased infection risk, and rare cases of lymphoma or skin cancer are the primary worries. Regular blood tests monitor liver enzymes, blood counts, and antibody levels. Live vaccines are avoided while on therapy, and TB screening is mandatory before starting.

Can treatment stop once remission is reached?

Most pediatric protocols continue scheduled dosing to prevent relapse. A minority of children who achieve deep remission and have undetectable antibodies may attempt supervised withdrawal, but relapse rates exceed 50 % within two years.